Molecular pathology of non-small cell lung cancer |
| |
| Affiliation: | 1. Division of Gastroenterology, University of South Alabama, 6000 University Commons, 75 University Boulevard South, Mobile, AL 36688, USA;2. Division of Hepatology, University of South Alabama, 6000 University Commons, 75 University Boulevard South, Mobile, AL 36688, USA;1. Mater Research Institute – University of Queensland, Level 3 Aubigny Place, Raymond Terrace, South Brisbane, Queensland 4101, Australia;2. School of Medicine, The University of Queensland, 288 Herston Road, Herston, Queensland 4006, Australia;1. Department of Pediatric Oncology, Emma Children’s Hospital/Academic Medical Center, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands;2. Department of Epidemiology, The Netherlands Cancer Institute, P.O. Box 90203, 1066 CX Amsterdam, The Netherlands;3. Department of Pediatric Oncology and Hematology, University of Groningen, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands;1. Institute of Pathology, University of Bonn, Germany;2. Institute of Pathology, University of Bern, Switzerland;3. Institute of Pathology, Section for Prostate Cancer Research, University of Bonn, Germany;4. Department of Urology, Charite'' – Universitätsmedizin Berlin, Berlin;5. Berlin Institute for Urologic Research, Berlin;6. Institute of Pathology, Charite'' – Universitätsmedizin Berlin, Berlin, Germany |
| |
| Abstract: | Our increasing understanding of the molecular pathogenesis of non-small cell lung cancer (NSCLC), particularly adenocarcinomas, has opened the door to ‘personalised medicine’ and the advent of new therapeutic strategies. Over the last few years new drugs, or classes of drugs, have been licensed and entered clinical practice for use in advanced NSCLC. The activity of these drugs is dependent on the presence of specific molecular or protein changes in cancer cells which are usually identified using ‘companion diagnostic tests’ specifically designed for this purpose. Pathologists and Pathology Departments have had to forge new links with Clinical Scientists in order to facilitate these additional investigations on the, often limited, tissue obtained for diagnosis. This collaboration plays a critical role in providing the link that allows integration of the traditional morphological diagnosis with the results of these new ‘companion diagnostic’ tests to guide patient management. |
| |
| Keywords: | adenocarcinoma molecular pathology non-small cell lung cancer pathology PD-L1 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
